Back to search

Peptide record

TPDB03296

PTP4 Antibacterial Anticancer Toxicity standard
24 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB03296
PTP4
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab
standard
No
A 24-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3, dbAMP, Peptipedia, and other sources, with an available 3D structural model.
Sequence
FLKLLKKLAAKFLPTIICKISYKC
Physicochemical Analysis
C135H228N30O28S2
RNDEQGHMWV
K
2783.60
10.36
6
0
13
+6
-1.09
0.788
138.33
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
1615
58.02
5
Residue Composition
number
2
A
0
R
0
N
0
D
2
C
0
E
0
Q
0
G
0
H
3
I
5
L
6
K
0
M
2
F
1
P
1
S
1
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 2 R: 0 N: 0 D: 0 C: 2 E: 0 Q: 0 G: 0 H: 0 I: 3 L: 5 K: 6 M: 0 F: 2 P: 1 S: 1 T: 1 W: 0 Y: 1 V: 0
Chemical Descriptors
24
C135H228N30O28S2
2783.60
10.36
+6
-1.09
0.788
Free
L
Linear
Free
Antibacterial
Gaegurin
Evidence Records 7 records
Evidence 1 Activity

Activity

IC50
IC50=13.71 µg/ml
Anticancer
13.71 µg/mL

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=26.15 µg/ml
Anticancer
26.15 µg/mL

Target

Renal Cancer
293
Renal

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003
Evidence 3 Activity

Activity

IC50
IC50=18.63 µg/ml
Anticancer
18.63 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003
Evidence 4 Activity

Activity

IC50
IC50=18.18 µg/ml
Anticancer
18.18 µg/mL

Target

Liver Cancer
Hep3B
Liver

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003
Evidence 5 Activity

Activity

IC50
IC50=18.1 µg/ml
Anticancer
18.1 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003
Evidence 6 Activity

Activity

IC50
Toxicity
26.15±6.23 µg/mL
Cytotoxic
IC50 | 26.15±6.23 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. | Peptides | 2003
Evidence 7 Activity

Activity

IC50
Toxicity
26.15
Hemolytic Cytotoxic
Hemolytic_activity: Human RBCs: 45.17% hemolysis at 100 µg/ml | Cytotoxicity: HEK293: IC50=26.15 ± 6.23 µg/ml

Target

erythrocytes

Source & Reference

NA
DRAMP
Peptides. 2003 Jul 24(7):945-53.